Radvanyi joins Genesis Biopharma

Wednesday, July 6, 2011 10:19 AM

Genesis Biopharma, a biotechnology company developing targeted cancer therapies, has named Laszlo Radvanyi, Ph.D., to its Scientific and Medical Advisory Board.

"Dr. Radvanyi's research using tumor-infiltrating lymphocytes (TILs) for the treatment of Stage IV metastatic melanoma, including ongoing phase I and phase II clinical trials, complements the development of our product candidate Contego for the treatment of Stage IV metastatic melanoma," stated Anthony J. Cataldo, chairman and CEO of Genesis Biopharma. 

Dr. Radvanyi worked in the immunology group at Sanofi-Pasteur in Toronto as a senior scientist, and later joined the faculty of the University of Texas, MD Anderson Cancer Center as an Associate Professor. 



Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs